Vir Biotech CEO Says His Covid-19 Medicine Offers Promise for Next Outbreak

(Bloomberg) — Vir Biotechnology Inc.’s stock has lost some of its luster after quadrupling earlier this year as competition heats up for Covid-19 antibody therapies. Yet its chief executive officer is looking ahead to the next viral scourge.


Load Error

With two well-heeled competitors ahead of it, Vir has pared a February surge to a still impressive 115% leap this year. Eli Lilly & Co.’s antibody treatment received an emergency use authorization on Nov. 9 and Regeneron Pharmaceuticals Inc.’s therapy got its nod over the weekend. Vir’s medicine is unique because it targets a variety of coronaviruses, CEO George Scangos said.

It “has the potential not only to be effective against Covid-19, but it has a reasonable chance of also being effective against the next coronavirus outbreak,” Scangos said in an interview. An interim look at late-stage data for VIR-7831 is expected in January.

Regeneron has touted its two-antibody cocktail

Read More

COVID-19 app payment loophole won’t be fixed by the end of England lockdown | Science & Tech News, Reports

People who are told to isolate by the contact tracing app will not be able to claim financial support after lockdown ends, and may not be able to before Christmas, Sky News can reveal.

Workers with low incomes in England are entitled to receive £500 if they cannot work from home while they self-isolate, but they can only claim the support if they are given a code by a human contact tracer.

Leaked documents seen by Sky News reveal that a technical fix has been drawn up and signed off by the Treasury and Downing Street.

Yet delays in its implementation mean it will not be in place for the end of England’s lockdown on December 2, and may not arrive for several weeks after that, despite fears that contacts will increase over the holiday period.

A leaked document shows the plan for the proposed fix

Labour called on

Read More

Trust The Science, But Celebrate The Business Of Covid-19 Vaccines

Written with Mahka Moeen

When it comes to fighting a pandemic like Covid-19, most people trust the science. They have less confidence in business to do the right thing. Industry leaders score high in competence on the 2020 Edelman Trust Barometer, but low on ethics.

Companies racing to deliver vaccines might have to confront that perception in the coming weeks. Even if they solve all the associated challenges in record time, public appreciation for their work might not climb.

Many people simply won’t notice. They read news reports of research teams developing vaccines at Pfizer, BioNTech, Moderna and AstraZeneca, and they applaud the power of science. Then they wait for supplies to show up at their local clinics. 

Nobody doubts this will happen. The worst-case scenario would be rationing during the initial months, which might cause jostling for position at the front of the line. Yet no one imagines

Read More

Foldable Smartphone Market Research Report with Industry Share, Size and Strategies to Boost Growth: Covid-19 Impact And Recovery

The MarketWatch News Department was not involved in the creation of this content.

Nov 24, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

“Foldable Smartphone Market” research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Foldable Smartphone Market Report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Foldable Smartphone market standing, enterprise competition outline, welfares and drawbacks of enterprise stock, Foldable Smartphone industry development trends, regional industrial layout features and economics policies, industry News and Strategies by Regions has additionally been enclosed.

Get a Sample Copy of the Report at-

In Regional Analysis, the Foldable Smartphone market is also categorised into North America, Europe, China, Japan, the middle East, India, South America, Others. North America,

Read More

DECN XPRIZE Testing Data for Rapid COVID-19 Testing Technology Yields Near Textbook Results

Data using XPRIZE supplied contrived fluid samples provides results comparable to those seen in the FDA lab testing of donor saliva, as DECN competes for the $5 million prize and GLOBAL validation

LOS ANGELES, CA / ACCESSWIRE / November 23, 2020 / Decision Diagnostics Corp. (OTC:DECN), a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters along with its subsidiary Pharma Tech Solutions, Inc., the inventor/manufacturer of the GenViro! Covid-19 Swift Kit truly rapid testing methodology, today announced the results of the completion of its testing for the world-renown XPRIZE, The results from the GenViro! testing, using simulated Covid samples and protocols provided by XPRIZE, provided results in 4-9 seconds that were consistent with what the company reports seeing in the FDA lab human donor testing it is concluding at its certified lab and from human donor tests run in the

Read More

Covid-19 vaccines may hurt. CDC’s ACIP says people need to know this upfront

The CDC’s Advisory Committee on Immunization Practices met to discuss whether to recommend use of any Covid-19 vaccine that the US Food and Drug Administration might authorize.

Volunteers in vaccine trials have reported they frequently feel flu-like effects after getting vaccinated, and members of the ACIP — as well as liaison representatives who take part in the discussion — said that could affect people’s willingness to get vaccinated in the first place, or to get the second dose of the two-vaccine regimen.

“As a practicing physician, I have got to be sure my patients will come back for the second dose. We really have got to make patients aware that this is not going to be a walk in the park,” Dr. Sandra Fryhofer of the Emory University School of Medicine, representing the American Medical Association, told the meeting.

“They are going to know they got a vaccine. They are … Read More

Walz to announce new COVID-19 technology, Minnesota releases app

Downloading the app is completely voluntary, and Gov. Tim Walz said no private information will be stored by the state, Google or Apple.

ST PAUL, Minn. — The state of Minnesota has released a new app to alert people if they’ve been exposed to someone with COVID-19.

Governor Tim Walz spoke Monday about the new technology he says will help Minnesota slow the spread of the virus. He’s asking all Minnesotans to download the app in the Google Play Store or Apple App Store.

At a news conference at 12:30 p.m., Walz was joined by public health official Kris Ehresmann and Minnesota IT Services Commissioner Tarek Tomes. 

“COVID is not going to end at the end of the month,” Walz said. “We are in an unrelenting spike.”

The Minnesota COVID-19 exposure notification app is called COVIDaware MN. Walz called it another tool in the state’s toolbox to fight COVID-19. He

Read More

The risk of being exposed to COVID-19 at an event in Spokane

KREM 2 checked the risks in counties in Eastern Washington, North Idaho and part of Montana for three different sized events: 10-person, 50-person and 100-person.

SPOKANE, Wash — Thinking about attending a Thanksgiving dinner this year? In parts of the Inland Northwest, that could be almost like flipping a coin to see if you get the coronavirus, according to a tool built by Georgia Tech.

The university compiles data from the COVID Tracking Project and the New York Times COVID-19 data project to generate risk estimates for every county in the United States. You can use their tool – the Georgia Tech COVID-19 Event Risk Assessment Planning Tool – to get an idea of how likely you might be to catch to coronavirus if you attended an event of different sizes in any county in the country.

For example, in Spokane County, the tool calculates that at a 100-person event,

Read More

PEDSnet report details how COVID-19 pandemic has affected children — ScienceDaily

In the most comprehensive analysis to date of U.S. children tested and treated for COVID-19, an organization representing seven of the nation’s largest pediatric medical centers reports that some groups of children are faring significantly worse than children in general during the pandemic.

Findings from the PEDSnet organization — which includes Cincinnati Children’s — were published Nov. 23, 2020, in JAMA Pediatrics. The report is based on electronic medical records data from more than 135,000 children who have been tested for infections from the SARS-CoV-2 virus from Jan. 1 through Sept. 8, 2020.

“These findings are important because they improve our understanding of the impact of COVID-19 in the pediatric population,” says Nathan Pajor, MD, a pulmonary medicine specialist at Cincinnati Children’s and a co-author of the study. “We see that relative to adults, kids are less likely to have severe disease or to die from COVID-19. However, we

Read More

COVID-19 testing in Mass. is ‘far short’ of levels needed to stop the spread

Another takeaway: A ramped-up testing infrastructure will remain crucial to public health, well after vaccines are widely available.

“It’s not at the pace we would have expected,” said Donna Hochberg, a partner at consultancy Health Advances who leads the firm’s diagnostics practice. “Testing really does help control the pandemic.”

Bain Capital cochair Steve Pagliuca, who leads the tech council’s COVID-19 response and recovery efforts, hosted the event on Monday. The tech council’s main goal is to educate employers and public leaders about the continued need to focus on testing strategies even as the fight against COVID-19 enters a new phase with the arrival of vaccines. In its latest report on the issue, the tech council recommended that federal, state, and local governments develop a systematic, expanded testing regime using multiple kinds of tests and employing public-private partnerships.

Pagliuca, also a co-owner of the Boston Celtics, noted how the number of

Read More